Aim Immunoglobulin D （IgD） is a surface immunoglobulin that is expressed as either membrane IgD（mIgD） or secreted IgD （sIgD）. Researchers have shown that sIgD is often elevated in patients with autoimmune diseas...Aim Immunoglobulin D （IgD） is a surface immunoglobulin that is expressed as either membrane IgD（mIgD） or secreted IgD （sIgD）. Researchers have shown that sIgD is often elevated in patients with autoimmune diseases. The possible roles of sIgD on the function of peripheral blood mononuclear cells （PBMCs） in rheumatoid arthritis （RA） are still unclear and few studies have been performed. The objective of this study was to investigate the abnormal level of immunoglobulin D （IgD） and the effects of it by binding its receptor （IgDR） on peripheral blood mononuclear cells （PBMCs） in rheumatoid arthritis （RA）. Methods Blood samples were obtained from 54 RA patients and 42 healthy controls. The levels of sIgD, human soluble receptor activator of nuclear factor-KB lig- and （sRANKL）, anti-cyclic citrullinated peptide （anti-CCP）, C-reactive protein （CRP） were determined in ser- um samples by ELISA. Rheumatoid factor （RF） was detected by quantitative nephelometry. Erythrocytes sedimen- tation rate （ESR） was tested by Westergren method. IgDR and mIgD were detected by using flow cytometry. After PBMCs were cultured and treated with different concentrations of human IgD. PBMCs proliferation were measured by CCK-8, inflammatory cytokine production were assessed by inflammation antibody array, T-/B- cell subsets and IgDR expression were tested by flow cytometry. Results A significantly higher level of sIgD, mIgD and IgDR were detected in RA patients compared with healthy controls. The concentrations of sIgD were positively correlated with sRANKL, rheumatoid factor and C-reactive protein in RA patients. Strikingly, IgD could enhance the prolifer- ation of PBMCs and induce IL-lα, IL-1β, TNF-α, IL-6 and production from PBMCs. Moreover, the percentage of activated T cell subsets （ CD4 ＋ CD69 ＋ , CD4 ＋ CD154 ＋ ） and activated B cell subsets （ CD19 ＋ CD23 ＋ , CD19 ＋ CD21 ＋ , CD19 ＋ IgD ＋ and CD19- CD138 ＋ ） were increased by IgD. The percentage of unactivated T cell subset （CD4 ＋ CD62L ＋ ） and immature B cell subset （ CD19 ＋ IgM ＋ IgD- ） were decreased by IgD in PBMCs. Further- more, the expressions of IgDR on T and B cells were significantly increased by treatment with IgD. Conclusion IgD enhanced the activation of PBMCs through stimulation of IgDR, which may contribute to RA pathogenesis. IgD represents a potentially novel immunotherapeutic target for the management of RA.展开更多
Aim Paeoniflorin （Pae） is the principal bioactive component of total glucosides of peony （TGP）, which has been widely used in therapy for rheumatoid arthritis （RA）. Paeoniflorin-6＇-O-benzene sulfonate （code： ...Aim Paeoniflorin （Pae） is the principal bioactive component of total glucosides of peony （TGP）, which has been widely used in therapy for rheumatoid arthritis （RA）. Paeoniflorin-6＇-O-benzene sulfonate （code： CP-25） , a novel compound that is a newly ester derivatives of Pae, was evaluated in rats with adjuvant-induced ar- thritis （AA） to study its potential anti-arthritic activity. Methods AA rats were randomly divided into different groups and then treated with CP-25 （25, 50, 100 mg· kg^-1） and methotrexate （0. 5 mg · kg^-1）, from day 16 to day 32 after immunization. Arthritis severity was evaluated by clinical manifestation and histopathological examina- tion. The cells proliferation was determined by CCK-8 assay. Activities of IL-1β, IL-6, IL-17, IL-10, TGF-β1, TNF-oL, IIANKL and OPG were assessed by ELISA. The subsets of CD4 ＋T cells were assayed by flow cytometry. Results CP-25 treatment effectively reduced clinical severity scores and blinded histopathological scores compared with AA groups. CP-25-treated rats exhibited a decrease in the pro-inflammatory cytokines （IL-1β, IL-6, IL-17, and TNF-α） , coupled with an increase in the anti-inflammatory cytokines IL-10 and TGF-β1 in serum and macro- phages of AA rats. The flow cytometry analyses of CD4 ＋T cells dramatically demonstrated the immunomodulatory effects of CP-25 on abnormal immune dysfunction. Apart from the anti-inflammatory activity, treatment with CP-25 inhibited the fibroblast-like synoviocyte （FLS） activation and function. Furthermore, CP-25 treatment of AA rats restored the balance between RANKL and OPG in favor of its anti-osteoclastic effects. Conclusions Data presen- ted here demonstrated that administration of CP-25 significantly inhibited the progression of rat AA, with reductions both in arthritic inflammation and bone damage. The protective effects of CP-25 in AA highlight an attribute that is potential as an ideal new anti-arthritic agent for the treatment with human RA.展开更多
文摘Aim Immunoglobulin D （IgD） is a surface immunoglobulin that is expressed as either membrane IgD（mIgD） or secreted IgD （sIgD）. Researchers have shown that sIgD is often elevated in patients with autoimmune diseases. The possible roles of sIgD on the function of peripheral blood mononuclear cells （PBMCs） in rheumatoid arthritis （RA） are still unclear and few studies have been performed. The objective of this study was to investigate the abnormal level of immunoglobulin D （IgD） and the effects of it by binding its receptor （IgDR） on peripheral blood mononuclear cells （PBMCs） in rheumatoid arthritis （RA）. Methods Blood samples were obtained from 54 RA patients and 42 healthy controls. The levels of sIgD, human soluble receptor activator of nuclear factor-KB lig- and （sRANKL）, anti-cyclic citrullinated peptide （anti-CCP）, C-reactive protein （CRP） were determined in ser- um samples by ELISA. Rheumatoid factor （RF） was detected by quantitative nephelometry. Erythrocytes sedimen- tation rate （ESR） was tested by Westergren method. IgDR and mIgD were detected by using flow cytometry. After PBMCs were cultured and treated with different concentrations of human IgD. PBMCs proliferation were measured by CCK-8, inflammatory cytokine production were assessed by inflammation antibody array, T-/B- cell subsets and IgDR expression were tested by flow cytometry. Results A significantly higher level of sIgD, mIgD and IgDR were detected in RA patients compared with healthy controls. The concentrations of sIgD were positively correlated with sRANKL, rheumatoid factor and C-reactive protein in RA patients. Strikingly, IgD could enhance the prolifer- ation of PBMCs and induce IL-lα, IL-1β, TNF-α, IL-6 and production from PBMCs. Moreover, the percentage of activated T cell subsets （ CD4 ＋ CD69 ＋ , CD4 ＋ CD154 ＋ ） and activated B cell subsets （ CD19 ＋ CD23 ＋ , CD19 ＋ CD21 ＋ , CD19 ＋ IgD ＋ and CD19- CD138 ＋ ） were increased by IgD. The percentage of unactivated T cell subset （CD4 ＋ CD62L ＋ ） and immature B cell subset （ CD19 ＋ IgM ＋ IgD- ） were decreased by IgD in PBMCs. Further- more, the expressions of IgDR on T and B cells were significantly increased by treatment with IgD. Conclusion IgD enhanced the activation of PBMCs through stimulation of IgDR, which may contribute to RA pathogenesis. IgD represents a potentially novel immunotherapeutic target for the management of RA.
文摘Aim Paeoniflorin （Pae） is the principal bioactive component of total glucosides of peony （TGP）, which has been widely used in therapy for rheumatoid arthritis （RA）. Paeoniflorin-6＇-O-benzene sulfonate （code： CP-25） , a novel compound that is a newly ester derivatives of Pae, was evaluated in rats with adjuvant-induced ar- thritis （AA） to study its potential anti-arthritic activity. Methods AA rats were randomly divided into different groups and then treated with CP-25 （25, 50, 100 mg· kg^-1） and methotrexate （0. 5 mg · kg^-1）, from day 16 to day 32 after immunization. Arthritis severity was evaluated by clinical manifestation and histopathological examina- tion. The cells proliferation was determined by CCK-8 assay. Activities of IL-1β, IL-6, IL-17, IL-10, TGF-β1, TNF-oL, IIANKL and OPG were assessed by ELISA. The subsets of CD4 ＋T cells were assayed by flow cytometry. Results CP-25 treatment effectively reduced clinical severity scores and blinded histopathological scores compared with AA groups. CP-25-treated rats exhibited a decrease in the pro-inflammatory cytokines （IL-1β, IL-6, IL-17, and TNF-α） , coupled with an increase in the anti-inflammatory cytokines IL-10 and TGF-β1 in serum and macro- phages of AA rats. The flow cytometry analyses of CD4 ＋T cells dramatically demonstrated the immunomodulatory effects of CP-25 on abnormal immune dysfunction. Apart from the anti-inflammatory activity, treatment with CP-25 inhibited the fibroblast-like synoviocyte （FLS） activation and function. Furthermore, CP-25 treatment of AA rats restored the balance between RANKL and OPG in favor of its anti-osteoclastic effects. Conclusions Data presen- ted here demonstrated that administration of CP-25 significantly inhibited the progression of rat AA, with reductions both in arthritic inflammation and bone damage. The protective effects of CP-25 in AA highlight an attribute that is potential as an ideal new anti-arthritic agent for the treatment with human RA.
